FDA Expands REGAIN GBM Trial to 20 Patients; SNO Data Acceptance Signals Incremental Progress

What happened

Alpha Tau announced FDA approval of an IDE supplement expanding its U.S. recurrent glioblastoma REGAIN trial from 10 to 20 patients, with additional study endpoints and an interim analysis. An abstract authored by REGAIN principal investigator Dr. Joshua Palmer was accepted for presentation at the SNO 2026 Annual Meeting, marking the trial's first scientific meeting appearance. This represents a regulatory and clinical milestone, but it is not efficacy data; it signals FDA comfort with early safety and protocol adjustments. From an investor perspective, this adds another data point but does not significantly alter the near-term catalysts, which remain Japan PMS enrollment and the Q2 2026 GBM first-three-patient safety readout. The master report's WAIT rating and $7.75 base-case value appear unchanged given this news.

Implication

The FDA expansion to 20 patients and acceptance of interim analysis suggests the agency is comfortable with the safety profile so far, which is mildly positive. However, it also extends the timeline for full data and does not provide efficacy evidence. The SNO presentation will provide the first external validation of the trial design and early results, but it is not a definitive readout. Investors should continue to monitor the Q2 2026 safety readout from the first three patients and Japan PMS enrollment as the primary value drivers. The news does not change the WAIT rating, attractive entry at $6.00, or trim above $9.00.

Thesis delta

The thesis is unchanged: value depends on Japan Shonin conversion and time-boxed clinical milestones. The FDA expansion and SNO acceptance modestly increase confidence in GBM execution but do not provide new efficacy data. The investment stance remains WAIT.